204 related articles for article (PubMed ID: 32334108)
1. Neuronal Spleen tyrosine kinase (SYK) mediates cytokine release in Transgenic Tau P301S mice organotypic brain slice cultures.
Schweig JE; Yao H; Jin C; Crawford F; Mullan M; Paris D
Neurosci Lett; 2020 Jun; 729():134992. PubMed ID: 32334108
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
Schweig JE; Yao H; Beaulieu-Abdelahad D; Ait-Ghezala G; Mouzon B; Crawford F; Mullan M; Paris D
Acta Neuropathol Commun; 2017 Sep; 5(1):69. PubMed ID: 28877763
[TBL] [Abstract][Full Text] [Related]
3. Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation
Schweig JE; Yao H; Coppola K; Jin C; Crawford F; Mullan M; Paris D
J Biol Chem; 2019 Sep; 294(36):13378-13395. PubMed ID: 31324720
[TBL] [Abstract][Full Text] [Related]
4. Organotypic brain slice cultures of adult transgenic P301S mice--a model for tauopathy studies.
Mewes A; Franke H; Singer D
PLoS One; 2012; 7(9):e45017. PubMed ID: 22984603
[TBL] [Abstract][Full Text] [Related]
5. Distribution of spleen tyrosine kinase and tau phosphorylated at tyrosine 18 in a mouse model of tauopathy and in the human hippocampus.
Köhler C; Fuhr V; Dinekov M
Brain Res; 2017 Dec; 1677():1-13. PubMed ID: 28919467
[TBL] [Abstract][Full Text] [Related]
6. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.
Shi Y; Yamada K; Liddelow SA; Smith ST; Zhao L; Luo W; Tsai RM; Spina S; Grinberg LT; Rojas JC; Gallardo G; Wang K; Roh J; Robinson G; Finn MB; Jiang H; Sullivan PM; Baufeld C; Wood MW; Sutphen C; McCue L; Xiong C; Del-Aguila JL; Morris JC; Cruchaga C; ; Fagan AM; Miller BL; Boxer AL; Seeley WW; Butovsky O; Barres BA; Paul SM; Holtzman DM
Nature; 2017 Sep; 549(7673):523-527. PubMed ID: 28959956
[TBL] [Abstract][Full Text] [Related]
7. The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.
Paris D; Ait-Ghezala G; Bachmeier C; Laco G; Beaulieu-Abdelahad D; Lin Y; Jin C; Crawford F; Mullan M
J Biol Chem; 2014 Dec; 289(49):33927-44. PubMed ID: 25331948
[TBL] [Abstract][Full Text] [Related]
8. The behavioural and neuropathologic sexual dimorphism and absence of MIP-3α in tau P301S mouse model of Alzheimer's disease.
Sun Y; Guo Y; Feng X; Jia M; Ai N; Dong Y; Zheng Y; Fu L; Yu B; Zhang H; Wu J; Yu X; Wu H; Kong W
J Neuroinflammation; 2020 Feb; 17(1):72. PubMed ID: 32093751
[TBL] [Abstract][Full Text] [Related]
9. Spreading of P301S Aggregated Tau Investigated in Organotypic Mouse Brain Slice Cultures.
Korde DS; Humpel C
Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139003
[TBL] [Abstract][Full Text] [Related]
10. Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice.
Chalermpalanupap T; Schroeder JP; Rorabaugh JM; Liles LC; Lah JJ; Levey AI; Weinshenker D
J Neurosci; 2018 Jan; 38(1):74-92. PubMed ID: 29133432
[TBL] [Abstract][Full Text] [Related]
11. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.
van Olst L; Verhaege D; Franssen M; Kamermans A; Roucourt B; Carmans S; Ytebrouck E; van der Pol SMA; Wever D; Popovic M; Vandenbroucke RE; Sobrino T; Schouten M; de Vries HE
Neurobiol Aging; 2020 May; 89():89-98. PubMed ID: 32008854
[TBL] [Abstract][Full Text] [Related]
12. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice.
Jiang T; Zhang YD; Chen Q; Gao Q; Zhu XC; Zhou JS; Shi JQ; Lu H; Tan L; Yu JT
Neuropharmacology; 2016 Jun; 105():196-206. PubMed ID: 26802771
[TBL] [Abstract][Full Text] [Related]
13. Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions.
Sidoryk-Wegrzynowicz M; Gerber YN; Ries M; Sastre M; Tolkovsky AM; Spillantini MG
Acta Neuropathol Commun; 2017 Nov; 5(1):89. PubMed ID: 29187256
[TBL] [Abstract][Full Text] [Related]
14. P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice.
Ruan Z; Delpech JC; Venkatesan Kalavai S; Van Enoo AA; Hu J; Ikezu S; Ikezu T
Mol Neurodegener; 2020 Aug; 15(1):47. PubMed ID: 32811520
[TBL] [Abstract][Full Text] [Related]
15. Complement C3a receptor antagonist alleviates tau pathology and ameliorates cognitive deficits in P301S mice.
Yao Y; Chang Y; Li S; Zhu J; Wu Y; Jiang X; Li L; Liu R; Ma R; Li G
Brain Res Bull; 2023 Aug; 200():110685. PubMed ID: 37330021
[TBL] [Abstract][Full Text] [Related]
16. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
17. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Fusion Suppresses Tau Pathology-Induced Neurodegeneration and Cognitive Decline.
Wang L; Liu M; Gao J; Smith AM; Fujioka H; Liang J; Perry G; Wang X
J Alzheimers Dis; 2021; 84(3):1057-1069. PubMed ID: 34602490
[TBL] [Abstract][Full Text] [Related]
19. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections.
Iba M; McBride JD; Guo JL; Zhang B; Trojanowski JQ; Lee VM
Acta Neuropathol; 2015 Sep; 130(3):349-62. PubMed ID: 26150341
[TBL] [Abstract][Full Text] [Related]
20. Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy.
Mazzaro N; Barini E; Spillantini MG; Goedert M; Medini P; Gasparini L
J Neurosci; 2016 Feb; 36(7):2086-100. PubMed ID: 26888921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
